NCT01635712View on ClinicalTrials.gov

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

February 28, 2017

Conditions
Cancer
Interventions
DRUG

SNX-5422

Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety

Trial Locations (5)

27157

Wake Forest Baptist Health, Winston-Salem

30901

Georgia Regents University Cancer Center, Augusta

37212

Vanderbilt-Ingram Cancer Center, Nashville

95817

UC Davis Comprehensive Cancer Center, Sacramento

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Esanex Inc.

INDUSTRY

NCT01635712 - Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies | Biotech Hunter | Biotech Hunter